Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Abstract Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through synthetic lethality and have emerged as promising anticancer t...
Main Authors: | Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-03-01
|
Series: | Drugs in R&D |
Online Access: | https://doi.org/10.1007/s40268-020-00301-8 |
Similar Items
-
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
by: Stergios Boussios, et al.
Published: (2019-08-01) -
Wise Management of Ovarian Cancer: On the Cutting Edge
by: Stergios Boussios, et al.
Published: (2020-05-01) -
Isolation and Purification of Poly (ADP-Ribose) Polymerase
by: Khan, M. G.
Published: (1977) -
The Antiviral Activities of Poly-ADP-Ribose Polymerases
by: Mathilde Malgras, et al.
Published: (2021-03-01) -
Proteomique fonctionnelle des poly(ADP-Ribose) polymerases
by: Moreel, Xavier
Published: (2010)